Conditions: Primary Inoperable Thymoma Local Recurrent Thymoma
Keywords: primary inoperable thymoma local recurrent thymoma reduction of tumor size SOM230 LAR
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 16
Healthy volunteers: no

Brief summary:
This is a monocenter, single-arm, open label phase II trial evaluating the effect of SOM230 LAR in adult patients with inoperable primary thymoma and thymoma metastasis (Masaoka II-IVa). SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks. The purpose of this trial is a proof of concept.

Detailed description:

Arms:
arm 1: SOM230 LAR in a dosage of 60 mg i.m. once every 4 weeks

Interventions: intervention 1: SOM230 LAR
Intervention descriptions: intervention 1: SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.

Protocol document: